• Targeted CRISPRi Delivery to Adipocytes Reduces Obesity and

  2026-04-20

  This study introduces a targeted, nonviral CRISPR interference system directed against Fabp4 in white adipocytes, resulting in significant amelioration of obesity, inflammation, hepatic steatosis, and insulin resistance in vivo. The work represents a major advance in precision gene therapy for metabolic diseases, offering new insights for tissue-specific intervention strategies.

• Rotigotine Hydrochloride: Innovations in Nose-to-Brain PD Re

  2026-04-20

  Explore the advanced role of Rotigotine hydrochloride as a dopamine D2/D3 receptor agonist in Parkinson's disease research, with a unique focus on nose-to-brain delivery and neuroprotective mechanisms. Gain in-depth insights into nanoparticle administration and evidence-based assay guidance.

• Paroxetine Mesylate: Applied Research Workflows in Oncology

  2026-04-19

  Paroxetine Mesylate stands at the intersection of psychiatric and oncology research, offering potent selective serotonin reuptake inhibition as well as multi-kinase targeting—most notably MET and ERBB3. This article delivers a detailed guide to experimental workflows, troubleshooting, and protocol enhancements for leveraging Paroxetine Mesylate in advanced cancer and neuropharmacology models.

• iPSC-Based Prescreening for Ultrarare Disease Clinical Trial

  2026-04-18

  Sequiera et al. introduce a platform using patient-derived induced pluripotent stem cells (iPSCs) to prescreen drug efficacy and safety in cases of ultrarare Leigh-like syndrome. This strategic approach enables more personalized and data-driven clinical trial enrollment decisions, addressing a critical limitation in rare disease research.

• PHF2 Drives Neuroinflammation in Alzheimer’s via Epigenetic

  2026-04-17

  The study by Yang et al. identifies the histone demethylase PHF2 as a pivotal regulator of inflammatory gene networks in Alzheimer’s disease (AD). Through integrative genomic and functional approaches, the research demonstrates that PHF2 upregulation exacerbates neuroinflammation and cognitive deficits, establishing PHF2 as a promising epigenetic target for AD intervention.

• Dual Enzyme-Responsive Zwitterionic Peptides for Cancer Sele

  2026-04-16

  This study introduces a peptide amphiphile that achieves high cancer selectivity by exploiting dual enzyme-responsive self-assembly in lysosomes. The approach minimizes off-target toxicity and demonstrates significant tumor regression in in vivo models, offering a promising strategy for peptide-based cancer therapeutics.

• CKI 7 Dihydrochloride: Advancing CK1 Inhibition in Oncology

  2026-04-15

  Explore how CKI 7 dihydrochloride, a selective Casein kinase 1 inhibitor from APExBIO, is revolutionizing translational research in cancer biology and circadian rhythm regulation. This article bridges mechanistic insight and strategic guidance, with a focus on actionable protocol parameters, competitive positioning, and translational opportunities for advanced signaling pathway dissection. Evidence from recent NSCLC metastasis studies and expert commentary contextualize CK1 inhibition within the evolving landscape of precision oncology.

• Decitabine (5-Aza-2'-deoxycytidine): Protocols, Use-Cases, a

  2026-04-14

  Decitabine (5-Aza-2'-deoxycytidine) empowers researchers to reactivate silenced tumor suppressor genes and modulate immune cell function in cancer and hematopoietic disease models. This guide delivers workflow enhancements, evidence-backed protocol parameters, and actionable troubleshooting tips for maximizing Decitabine’s impact in epigenetic experiments.

• Honokiol (N1672): NF-κB Pathway Inhibitor for Cancer Researc

  2026-04-13

  Honokiol is a bioactive compound with proven anti-inflammatory and antioxidant effects, acting as a potent NF-κB pathway inhibitor. Its high purity and solubility profile make it suitable for precise in vitro cancer research applications. APExBIO's Honokiol (SKU N1672) is validated for reproducibility and workflow integration.

• Precision Dimerization: AP20187 in Regulated Cell Therapy

  2026-04-12

  This thought-leadership article explores how AP20187, a synthetic chemical inducer of dimerization from APExBIO, empowers translational researchers to precisely control signaling and gene expression in vivo. By weaving mechanistic insights from recent discoveries in 14-3-3 protein networks and autophagy regulation into actionable guidance, we highlight AP20187’s pivotal role in advancing conditional gene therapy and regulated cell therapy. The discussion extends beyond standard product descriptions, offering a strategic vision for next-generation experimental design in cancer and metabolic research.

• Reactive Oxygen Species Assay Kit: Enhanced Quantification W

  2026-04-12

  Unlock reproducible, quantitative measurement of cellular ROS using the APExBIO Reactive Oxygen Species Assay Kit. Explore advanced protocol strategies, troubleshooting, and actionable insights that empower high-sensitivity oxidative stress research in live cells.

• Merimepodib (VX-497): Applied Workflows in Antiviral and Imm

  2026-04-11

  Merimepodib (VX-497) stands out as a versatile, selective, and reversible IMPDH inhibitor, enabling precise dissection of nucleotide biosynthesis in cancer, immunology, and antiviral models. This article translates recent mechanistic breakthroughs into actionable experimental workflows, highlighting data-driven parameter recommendations and troubleshooting strategies for high-impact research.

• Medroxyprogesterone Acetate in Decidualization & Renal Resea

  2026-04-11

  Medroxyprogesterone acetate (MPA) delivers reproducible control in endometrial and renal epithelial assays, enabling advanced study of hormone-dependent and -independent mechanisms. Leveraging rigorous workflow and the latest lipid metabolism insights, APExBIO’s MPA empowers researchers to dissect complex reproductive and renal biology with precision.

• Oteseconazole (VT-1161): Reliable Antifungal Agent for Se...

  2026-04-10

  This article delivers a scenario-driven exploration of Oteseconazole (VT-1161) (SKU BA1665) as a validated, evidence-based solution for cell viability and antifungal susceptibility assays. Readers will discover how SKU BA1665 addresses common laboratory challenges—from maintaining selectivity and reproducibility to optimizing workflows and ensuring vendor reliability—grounded in peer-reviewed data and practical experimental design. Use this resource to enhance assay confidence and streamline antifungal research with Oteseconazole (VT-1161).

• Oteseconazole (VT-1161): Mechanistic Precision and Strate...

  2026-04-09

  With invasive fungal infections on the rise and resistance outpacing traditional therapies, Oteseconazole (VT-1161) emerges as a next-generation tetrazole CYP51 inhibitor, offering translational researchers a targeted, selective, and clinically validated tool against Candida—including drug-resistant strains. This article bridges molecular insight, experimental best practices, and strategic foresight, delving deeper than standard product summaries to empower antifungal innovation.

407 records 18/28 page Previous Next First page 上5页 1617181920 下5页 Last page